Dianthus Therapeutics
Clinical trials sponsored by Dianthus Therapeutics, explained in plain language.
Biotech developing complement-targeted therapies for rare diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New drug aims to stop CIDP relapses in its tracks
Disease control Recruiting nowThis Phase 3 trial tests whether the drug claseprubart (DNTH103) can prevent relapses in adults with CIDP, a nerve disorder that causes weakness and disability. About 256 participants will receive either the drug or a placebo. The main goal is to see how long it takes for symptom…
Phase: PHASE3 • Sponsor: Dianthus Therapeutics • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug aims to ease daily struggles of myasthenia gravis
Disease control Recruiting nowThis phase 3 trial tests whether claseprubart (DNTH103) can improve symptoms of generalized myasthenia gravis, a condition causing muscle weakness. About 195 adults with a specific antibody type are randomly assigned to receive the drug or a placebo. The main goal is to see if th…
Phase: PHASE3 • Sponsor: Dianthus Therapeutics • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC